Clinical Application and Utility of PyLARIFY (18F DCFPyL) in Prostate Cancer Videos

NCCN Guidelines Update on Selection of PSMA PET Imaging Agent in Patient Selection for Lutetium-177–PSMA-617 - Oliver Sartor

Details
Oliver Sartor joins Alicia Morgans in a brief discussion on the Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer and how we can think about selecting patients for treatment with Lutetium-177–PSMA-617 using a PSMA PET scans. Biographies: A. Oliver Sartor, MD, Professor of Medicine and Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Rese...

PSMA-targeted PET Imaging of Prostate Cancer - A Primer for Urologists - Michael Gorin

Details
In this Society of Nuclear Medicine and Molecular Imaging (SNMMI), Satellite Symposium entitled PSMA-Targeted PET Imaging and Interpretation: What Urologists Need to Know Michael Gorin, MD presents on PSMA-targeted PET Imaging of Prostate Cancer - A Primer for Urologists. Dr. Gorin starts with reviewing conventional imaging modalities for prostate cancer which have proved insufficient for detectin...

PSMA PET/CT Imaging Indications in Prostate Cancer - Phillip Koo, Neal Shore, & Oliver Sartor

Details
Phillip Koo, Oliver Sartor, and Neal Shore discuss indications for PSMA PET/CT molecular imaging in patients with prostate cancer. Dr. Koo gives a background on PSMA PET/CT agents and breaks down indications into the two different patient subsets: patients with suspected metastasis who are candidates for initial definitive therapy and patients who have suspected recurrence based on elevated serum...

NCCN Guidelines On PSMA Molecular Imaging - Tanya Dorff

Details
Alicia Morgans and Tanya Dorff, discuss the updates to the NCCN guidelines since the approval of PSMA PET CT molecular imaging agents. They discuss new guidance based on the FDA-approved indications in the labels for the use of molecular imaging agents for detecting prostate cancer when PSA levels are still relatively low and when PSA levels are rising. Biographies: Tanya B. Dorff, MD., is an asso...

PYLARIFY®, F 18-labeled PSMA Targeted PET Gains US FDA Approval - Michael Morris

Details
Michael Morris, MD joins Charles Ryan, MD in a discussion on the United States (US) FDA Approval of PYLARIFY®, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent. The F 18 tracer went through two qualifying clinical trials the CONDOR trial and then OSPREY trial. This is the first time a national commercial approval will render PSMA i...

PSMA-Targeted PET Imaging Metastatic Disease, Response Assessment, Future Directions, and Read Paradigms - Steven Rowe

Details
In this Society of Nuclear Medicine and Molecular Imaging (SNMMI) Satellite Symposium entitled PSMA-Targeted PET Imaging and Interpretation: What Urologists Need to Know Steven Rowe, MD presents on PSMA-Targeted PET Imaging: Metastatic Disease, Response Assessment, Future Directions, and Read Paradigms. In his talk, he focuses on PSMA PET imaging in the context of metastatic disease, both small vo...

Symposium Discussion on PSMA-Targeted PET Imaging and Interpretation - What Urologists Need to Know

Details
Following presentations from Micheal Gorin and Steven Rowe during this Society of Nuclear Medicine and Molecular Imaging (SNMMI) Satellite Symposium entitled PSMA-Targeted PET Imaging and Interpretation: What Urologists Need to Know presented in conjunction with the American Urological Association Annual Meeting, the pair engage in a question and answer session. Drs. Gorin and Rowe comment on thei...

Practical Application of 18F-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer: The CONDOR Study - Michael Morris

Details
The CONDOR trial was one of two studies that supported the United States Federal Drug Administration (FDA) submission and subsequent approval of DCFPyL, an 18F radiolabeled PSMA directed PET tracer. The CONDOR trial focused specifically on the rising, the biochemically relapsed patient population, those who had surgery or radiation as their definitive primary therapy, biochemically relapsed, and t...

The Diagnostic Performance of PSMA PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY) - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss The Journal of Urology publication on the Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). Prostate cancer staging is critical in multiple steps in the disease continuum, from the initial diagnosis to the...

F-18-Labeled DCFPyL in Patients With Metastatic Prostate Cancer Undergoing Treatment With ADT – Esther Mena Gonzalez

Details
In this presentation from Esther Mena Gonzalez, she discusses her team’s findings on the role of castration status or hormone-sensitive castrate-resistance data and androgen deprivation therapy (ADT) in the use of 18F DCFPyL PET/CT. She discussed the objective of her study to be to investigate the performance of 18F DCFPyL in her cohort of patients with documented metastatic prostate cancer who we...
email news signup